- Home
- LDI vs SGMT Comparison
LDI vs SGMT Comparison
Compare LDI & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDI
- SGMT
- Stock Information
- Founded
- LDI 2010
- SGMT 2006
- Country
- LDI United States
- SGMT United States
- Employees
- LDI N/A
- SGMT N/A
- Industry
- LDI Finance: Consumer Services
- SGMT
- Sector
- LDI Finance
- SGMT
- Exchange
- LDI Nasdaq
- SGMT Nasdaq
- Market Cap
- LDI 221.2M
- SGMT 230.3M
- IPO Year
- LDI 2021
- SGMT 2023
- Fundamental
- Price
- LDI $3.55
- SGMT $7.15
- Analyst Decision
- LDI Sell
- SGMT Strong Buy
- Analyst Count
- LDI 3
- SGMT 7
- Target Price
- LDI $2.30
- SGMT $26.57
- AVG Volume (30 Days)
- LDI 4.0M
- SGMT 601.4K
- Earning Date
- LDI 11-04-2025
- SGMT 08-13-2025
- Dividend Yield
- LDI N/A
- SGMT N/A
- EPS Growth
- LDI N/A
- SGMT N/A
- EPS
- LDI N/A
- SGMT N/A
- Revenue
- LDI $1,124,074,000.00
- SGMT N/A
- Revenue This Year
- LDI $21.95
- SGMT N/A
- Revenue Next Year
- LDI $15.72
- SGMT N/A
- P/E Ratio
- LDI N/A
- SGMT N/A
- Revenue Growth
- LDI 27.06
- SGMT N/A
- 52 Week Low
- LDI $1.01
- SGMT $1.73
- 52 Week High
- LDI $3.23
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- LDI 84.05
- SGMT 40.16
- Support Level
- LDI $1.81
- SGMT $7.01
- Resistance Level
- LDI $2.16
- SGMT $7.68
- Average True Range (ATR)
- LDI 0.23
- SGMT 0.49
- MACD
- LDI 0.12
- SGMT -0.02
- Stochastic Oscillator
- LDI 78.38
- SGMT 46.54
About LDI loanDepot Inc.
loanDepot Inc provides nonbank consumer lending solutions for individuals in the United States. It offers personal, residential home, home refinancing, mortgage and home equity loans. It also provides online mortgage loans for refinancing and home purchases. It serves customers through distribution channels, including consumer direct centres, retail branches, wholesale centres, and consumer finance and servicing centres in the United States. It competes with commercial banks and financial institutions.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.